Teva Pharmaceutical Industries (NYSE:TEVA) Earns “Neutral” Rating from Credit Suisse Group

Credit Suisse Group reiterated their neutral rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a report issued on Wednesday morning, Briefing.com Automated Import reports.

A number of other research firms also recently issued reports on TEVA. Barclays reaffirmed a hold rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Argus initiated coverage on Ameriprise Financial in a research report on Friday, July 5th. They issued a buy rating on the stock. Mizuho set a $11.00 target price on Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Monday, June 17th. CIBC raised Centerra Gold from a neutral rating to an outperform rating and lifted their target price for the company from C$9.00 to C$10.50 in a research report on Monday, June 3rd. Finally, Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the company a neutral rating in a research report on Tuesday, June 18th. Five research analysts have rated the stock with a sell rating, fifteen have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of Hold and a consensus target price of $15.83.

Shares of TEVA opened at $9.25 on Wednesday. The company has a market cap of $9.12 billion, a price-to-earnings ratio of 3.30, a price-to-earnings-growth ratio of 1.07 and a beta of 1.62. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62. The company has a fifty day moving average price of $9.13. Teva Pharmaceutical Industries has a 52 week low of $7.96 and a 52 week high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. The firm had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.38 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. The business’s quarterly revenue was down 15.2% compared to the same quarter last year. During the same period last year, the company earned $0.94 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries will post 2.27 earnings per share for the current fiscal year.

In related news, Director Sol J. Barer purchased 111,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was bought at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the purchase, the director now directly owns 115,942 shares in the company, valued at approximately $1,041,159.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Notaristefani Carlo De sold 16,070 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now owns 49,659 shares of the company’s stock, valued at approximately $567,105.78. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

Several hedge funds have recently modified their holdings of TEVA. Cutler Capital Management LLC acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth $2,539,000. Prudential Financial Inc. boosted its position in Teva Pharmaceutical Industries by 105.5% during the 4th quarter. Prudential Financial Inc. now owns 218,134 shares of the company’s stock worth $3,364,000 after acquiring an additional 111,965 shares during the period. Bank of New York Mellon Corp boosted its position in Teva Pharmaceutical Industries by 3.5% during the 4th quarter. Bank of New York Mellon Corp now owns 1,975,038 shares of the company’s stock worth $30,454,000 after acquiring an additional 67,168 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Teva Pharmaceutical Industries by 2.0% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 76,187 shares of the company’s stock worth $1,175,000 after acquiring an additional 1,497 shares during the period. Finally, Northern Trust Corp boosted its position in Teva Pharmaceutical Industries by 2.7% during the 4th quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock worth $103,125,000 after acquiring an additional 175,173 shares during the period. Institutional investors own 65.08% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: Is a Roth IRA right for you?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.